Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Quidel's molecular diagnostic test, Quidel molecular influenza A+B assay, used for the identification of influenza A and B.
Subscribe to our email newsletter
Following approval, the company will market its influenza A+B assay in the US.
Quidel’s product portfolio includes PCR reagent kits for use by molecular diagnostic laboratories with its existing Applied Biosystems 7500 Fast DX thermocycler.
Quidel president and CEO Douglas Bryant said the Quidel molecular influenza A+B assay provides users a reliable, easy-to-use option for the diagnosis of influenza virus infections.
"We are very pleased with the timely FDA clearance of this molecular product," Bryant added.
The assay was launched in Europe in August 2011.